Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform | News Direct

Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform

HemoGenyx Pharmaceuticals
News release by HemoGenyx Pharmaceuticals

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | February 20, 2024 08:09 AM Eastern Standard Time


Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.

Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolises a pivotal milestone, offering potential life-changing treatments for patients with limited options.

Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.

As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike.


Contact Details


Proactive UK Ltd


Proactive UK Ltd


+44 20 7989 0813



project media


HealthMedicinePharmaBiotechCancerOncologyLeukemiaViral Infections